LISINOPRIL AND HYDROCHLOROTHIAZIDE

Lisinopril And Hydrochlorothiazide Adverse Events Reported to the FDA Over Time

How are Lisinopril And Hydrochlorothiazide adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Lisinopril And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Lisinopril And Hydrochlorothiazide is flagged as the suspect drug causing the adverse event.

Most Common Lisinopril And Hydrochlorothiazide Adverse Events Reported to the FDA

What are the most common Lisinopril And Hydrochlorothiazide adverse events reported to the FDA?

Angioedema	212 (5.1%)
Cough	128 (3.08%)
Dizziness	92 (2.21%)
Renal Failure Acute	75 (1.81%)
Fatigue	62 (1.49%)
Dyspnoea	59 (1.42%)
Nausea	56 (1.35%)
Hypotension	54 (1.3%)
Drug Ineffective	50 (1.2%)
Blood Pressure Increased	46 (1.11%)
Completed Suicide	43 (1.04%)
	Show More
Dehydration	42 (1.01%)
Hypoaesthesia	40 (.96%)
Diarrhoea	38 (.91%)
Swollen Tongue	38 (.91%)
Headache	37 (.89%)
Pain	37 (.89%)
Syncope	37 (.89%)
Asthenia	36 (.87%)
Dysphagia	36 (.87%)
Hypertension	36 (.87%)
Pruritus	34 (.82%)
Malaise	32 (.77%)
Swelling Face	32 (.77%)
Paraesthesia	31 (.75%)
Muscle Spasms	30 (.72%)
Insomnia	28 (.67%)
Vomiting	28 (.67%)
Feeling Abnormal	26 (.63%)
Rash	26 (.63%)
Arthralgia	25 (.6%)
Blood Creatinine Increased	25 (.6%)
Confusional State	25 (.6%)
Back Pain	24 (.58%)
Lip Swelling	24 (.58%)
Burning Sensation	23 (.55%)
Hypersensitivity	23 (.55%)
Hyponatraemia	23 (.55%)
Drug Interaction	22 (.53%)
Product Substitution Issue	22 (.53%)
Chest Pain	21 (.51%)
Pharyngeal Oedema	21 (.51%)
Drug Hypersensitivity	20 (.48%)
Cardiac Arrest	19 (.46%)
Gait Disturbance	19 (.46%)
Hyperhidrosis	19 (.46%)
Vision Blurred	19 (.46%)
Heart Rate Increased	18 (.43%)
Hyperkalaemia	18 (.43%)
Medication Error	18 (.43%)
Muscular Weakness	18 (.43%)
Musculoskeletal Pain	18 (.43%)
Respiratory Arrest	17 (.41%)
Urosepsis	17 (.41%)
Urticaria	17 (.41%)
Weight Increased	17 (.41%)
Blood Pressure Decreased	16 (.39%)
Fall	16 (.39%)
Pain In Extremity	16 (.39%)
Tremor	16 (.39%)
Abdominal Pain Upper	15 (.36%)
Blood Glucose Increased	15 (.36%)
Somnolence	15 (.36%)
Breast Swelling	14 (.34%)
Loss Of Consciousness	14 (.34%)
Product Quality Issue	14 (.34%)
Speech Disorder	14 (.34%)
Blood Pressure Systolic Increased	13 (.31%)
Death	13 (.31%)
Fluid Overload	13 (.31%)
Palpitations	13 (.31%)
Renal Failure	13 (.31%)
Abdominal Pain	12 (.29%)
Decreased Appetite	12 (.29%)
Dyskinesia	12 (.29%)
Hypokalaemia	12 (.29%)
Myalgia	12 (.29%)
Oedema Peripheral	12 (.29%)
Throat Irritation	12 (.29%)
Weight Decreased	12 (.29%)
Blood Sodium Decreased	11 (.26%)
Chest Discomfort	11 (.26%)
Coagulation Factor Viii Level Decre...	11 (.26%)
Coagulation Time Prolonged	11 (.26%)
Dysphonia	11 (.26%)
Haematoma	11 (.26%)
Intentional Drug Misuse	11 (.26%)
Neck Pain	11 (.26%)
Pneumonia	11 (.26%)
Rash Erythematous	11 (.26%)
Unresponsive To Stimuli	11 (.26%)
Wheezing	11 (.26%)
Abdominal Discomfort	10 (.24%)
Condition Aggravated	10 (.24%)
Depressed Level Of Consciousness	10 (.24%)
Depression	10 (.24%)
Dialysis	10 (.24%)
Intentional Overdose	10 (.24%)
Lactic Acidosis	10 (.24%)
Oropharyngeal Pain	10 (.24%)
Pancreatitis	10 (.24%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Lisinopril And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lisinopril And Hydrochlorothiazide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Lisinopril And Hydrochlorothiazide

What are the most common Lisinopril And Hydrochlorothiazide adverse events reported to the FDA?

Neurological	351 (8.45%)
Respiratory	291 (7.01%)
Angiedema And Urticaria	229 (5.51%)
Gastrointestinal Signs	189 (4.55%)
Epidermal And Dermal Conditions	188 (4.53%)
Cardiac And Vascular Investigations	117 (2.82%)
Electrolyte And Fluid Balance Condi...	117 (2.82%)
Renal Disorders	116 (2.79%)
Therapeutic And Nontherapeutic Effe...	103 (2.48%)
Musculoskeletal And Connective Tiss...	86 (2.07%)
Decreased And Nonspecific Blood Pre...	73 (1.76%)
	Show More
Medication Errors	72 (1.73%)
Muscle	71 (1.71%)
Allergic Conditions	64 (1.54%)
Infections - Pathogen Unspecified	63 (1.52%)
Cardiac Arrhythmias	57 (1.37%)
Oral Soft Tissue Conditions	55 (1.32%)
Gastrointestinal Motility And Defec...	54 (1.3%)
Joint	51 (1.23%)
Suicidal And Self-injurious Behavio...	47 (1.13%)
Tongue Conditions	45 (1.08%)
Movement Disorders	44 (1.06%)
Sleep Disorders	43 (1.04%)
Headaches	41 (.99%)
Product Quality Issues	40 (.96%)
Injuries	39 (.94%)
Vascular Hypertensive	39 (.94%)
Hematology Investigations	38 (.91%)
Upper Respiratory Tract Disorders	38 (.91%)
Renal And Urinary Tract Investigati...	37 (.89%)
Deliria	34 (.82%)
Physical Examination Topics	30 (.72%)
Anxiety Disorders	29 (.7%)
Urinary Tract Signs	29 (.7%)
Glucose Metabolism Disorders	27 (.65%)
Skin Appendage Conditions	27 (.65%)
Bronchial Disorders	26 (.63%)
Vision	26 (.63%)
Metabolic, Nutritional And Blood Ga...	25 (.6%)
Water, Electrolyte And Mineral	25 (.6%)
Appetite And General Nutritional	24 (.58%)
Central Nervous System Vascular	24 (.58%)
Psychiatric	24 (.58%)
Cardiac Disorder Signs	21 (.51%)
Lifestyle Issues	21 (.51%)
Mental Impairment	19 (.46%)
Chemical Injury And Poisoning	18 (.43%)
Exocrine Pancreas Conditions	16 (.39%)
Breast	15 (.36%)
Disturbances In Thinking	15 (.36%)
Fatal Outcomes	14 (.34%)
Hematological And Lymphoid Tissue T...	14 (.34%)
Vascular	14 (.34%)
Acid-base	13 (.31%)
Dental And Gingival Conditions	13 (.31%)
Bone And Joint Injuries	12 (.29%)
Vascular Hemorrhagic	12 (.29%)
Connective Tissue Disorders	11 (.26%)
Depressed Mood Disorders	11 (.26%)
Lower Respiratory Tract Disorders	11 (.26%)
Body Temperature Conditions	10 (.24%)
Enzyme	10 (.24%)
Therapeutic Procedures And Supporti...	10 (.24%)
Viral Infectious	10 (.24%)
Bacterial Infectious	9 (.22%)
Changes In Physical Activity	9 (.22%)
Hepatic And Hepatobiliary	9 (.22%)
Hepatobiliary	9 (.22%)
Inner Ear And Viiith Cranial Nerve	9 (.22%)
Mood Disorders	9 (.22%)
Salivary Gland Conditions	9 (.22%)
Aural	8 (.19%)
Gastrointestinal Conditions	8 (.19%)
Hearing	8 (.19%)
Lipid Analyses	8 (.19%)
Seizures	8 (.19%)
Toxicology And Therapeutic Drug Mon...	8 (.19%)
Cranial Nerve Disorders	7 (.17%)
Gastrointestinal Inflammatory Condi...	7 (.17%)
Personality Disorders	7 (.17%)
Purine And Pyrimidine Metabolism	7 (.17%)
Thyroid Gland	7 (.17%)
Anemias Nonhemolytic And Marrow Dep...	6 (.14%)
Coronary Artery	6 (.14%)
Eye	6 (.14%)
Lipid Metabolism	6 (.14%)
Miscellaneous And Site Unspecified ...	6 (.14%)
Placental, Amniotic And Cavity Diso...	6 (.14%)
Procedural And Device Related Injur...	6 (.14%)
Respiratory And Mediastinal Neoplas...	6 (.14%)
Arteriosclerosis, Stenosis, Vascula...	5 (.12%)
Bone Disorders	5 (.12%)
Eating Disorders	5 (.12%)
Sexual Dysfunctions, Disturbances A...	5 (.12%)
Administration Site Reactions	4 (.1%)
Bone, Calcium, Magnesium And Phosph...	4 (.1%)
Coagulopathies And Bleeding Diathes...	4 (.1%)
Embolism And Thrombosis	4 (.1%)
Neurological Disorders Congenital	4 (.1%)
Obstetric And Gynecological Therape...	4 (.1%)
Peripheral Neuropathies	4 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Lisinopril And Hydrochlorothiazide, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Lisinopril And Hydrochlorothiazide is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.